Double-blind comparison of moclobemide
and tranylcypromine in depression


Heinze G, Rossel L, Gabelic I, Galeano-Munoz J, Stabl M, Allen SR

Instituto Mexicano de Psiquiatria, Mexico, D.F. 
Pharmacopsychiatry 1993 Nov; 26(6):240-5

ABSTRACT

Moclobemide is the first of a new generation of reversible inhibitors of monoamine oxidase-A (RIMA) with no clinically relevant potentiation of the hypertensive actions of dietary tyramine. The present study was conducted to compare the efficacy and safety of moclobemide with an established irreversible monoamine oxidase inhibitor, tranylcypromine, in depressed patients. Patients were randomized to receive moclobemide (81 patients) or tranylcypromine (79 patients) at individually titrated doses (100-300 mg/day of moclobemide and 10-30 mg/day of tranylcypromine) under double-blind conditions for at least four weeks, in a multicenter trial. Antidepressant efficacy was assessed using items 1-17 of the Hamilton depression rating scale (HAMD-17), the von Zerssen 'Befindlichkeits' scales, a visual analog scale and the clinicians' global impression. Both treatments resulted in significant amelioration of depression as determined by all rating instruments. HAMD-17 scores were reduced by 63% and 58% with moclobemide and tranylcypromine respectively, although the difference between the groups was not significant. The other rating instruments yielded similar results, apart from the clinician's assessment of efficacy at day 28. In this assessment, efficacy was rated as very good/good in 78% of moclobemide treated patients and in 88% of the tranylcypromine treated patients; however, only patients who had not dropped out of the trial were included in this assessment. The tolerability of both drugs was good, although moclobemide appeared to possess a small advantage in this regard since only one patient in this group was prematurely withdrawn from the trial due to inadequate tolerability/adverse events, compared with nine withdrawals in the tranycypromine group. 

Back                          to order

                  Moclobemide research

         1.    Moclobemide  for the treatment of depression
         2.    Moclobemide  in clinical psychopharmacology
         3.    Moclobemide  therapy for chronic depressive disorders 
         4.    Moclobemide  and tranylcypromine in depression
         5.    Moclobemide  and fluoxetine for panic disorder
         6.    Moclobemide  in patients with dementia and depression
         7.    Moclobemide  in mild major depression
         8.    Moclobemide  for depression
         9.    Moclobemide  in treatment of major depressive episodes
        10.   Moclobemide  vs. placebo in the treatment of depression
        11.   Moclobemide  long-term treatment in major depression
        12.   Moclobemide  and sertraline in the treatment of depression
        13.   Moclobemide  in long-term treatment
        14.   Moclobemide  vs fluoxetine for double depression
        15.   Moclobemide  vs fluoxetine in major depressive disorders
        16.   Moclobemide  vs fluoxetine in major depression

 

 

Hit Counter